Insulet (PODD) Earnings Analysis | Revenue +33.9%, Omnipod International Revenue +59.4% as Type 2 Market Expansion Accelerates [FY2026 Q1 Japanese Commentary]

Amid the widespread view that the rapid adoption of GLP-1 drugs means "diabetes patients can be cured with medication and will no longer need devices," Insulet (PODD)'s FY2026 Q1 results, with revenue up 33.9% and international revenue up 59.4%, provided a powerful answer that "devices are actually expanding." For type 1 diabetes patients, insulin administration is a lifelong treatment, and for type 2 diabetes, the label expansion for Omnipod 5 is also progressing in the US.The global expansion of tubeless automated insulin deliverywas the star of this quarter.

Summary of this quarter's earnings (3 lines)

・Total revenue +33.9%, International +59.4%, Omnipod revenue accelerating with high double-digit growth (US Omnipod $516 million / International $243 million / Total revenue $762 million) — Pharmacy channel and type 2 expansion drove the US, while switching to Omnipod 5 drove international growth.

・Net income +157%, Adjusted EBITDA +35.7%, simultaneous improvement in earnings quality (Net income $91 million / Adjusted EBITDA $182 million / Free CF $90 million) — SG&A leverage took effect, with the ratio to revenue falling from 45.8% to 41.6%, also aided by the completion of the $39.5 million debt extinguishment loss from the same period last year.

・Completed $300 million accelerated share repurchase, approved an additional $350 million to clarify return stance (Approximately 1.25 million shares repurchased in FY2026 Q1 / Program extended until December 2027) — Management decision demonstrating a balance between growth investment and shareholder returns.

Company Overview

In a nutshell, it is theworld's only mass-production player for tubeless insulin pumps. Omnipod is a patch-type insulin delivery device that does not require tubes and is worn continuously for 3 days. The latest generation, Omnipod 5, is an Automated Insulin Delivery (AID) system compatible with DexCom G6/G7 and Abbott FreeStyle Libre 2 Plus, and is indicated in the US for both type 1 and type 2 diabetes (18 years and older).

FY2025 full-year revenue was approximately $2.71 billion (approx. 422.8 billion yen), nearly 1.9 times higher in three years from $1.43 billion in FY2022. In the US, it is sold through the pharmacy channel, building patient access that overcomes the barriers of insurance reimbursement.

Three points for this quarter

Point 1: Revenue +33.9% and operating leverage is clearly taking effect

Total revenue was $762 million (approx. 118.9 billion yen), a +33.9% increase from $569 million in the same period last year, and high growth of +30.1% on a constant currency basis. What is noteworthy is the decline in the SG&A ratio, which shrank by 4.2 percentage points from 45.8% to 41.6% of revenue. This is the result of revenue growth significantly outpacing the increase in SG&A expenses, which is clear evidence that operating leverage is working.

Net income was $91 million (approx. 14.2 billion yen), up +157% year-on-year. However, caution is needed with this growth rate, as the same period last year included a $39.5 million debt extinguishment loss, and the disappearance of that special factor is included. Adjusted EBITDA, which more accurately reflects the actual situation, was $182 million (approx. 28.4 billion yen), up +35.7%, which shows the company's underlying earnings growth.

Point 2: Quality of growth seen by region, full-scale international expansion

International Omnipod revenue grew at a pace of +45.2% even on a constant currency basis, exceeding the US (+28.3%). The launch of Omnipod 5 in five Middle Eastern countries in February 2026, and the increase in unit prices due to the switch from DASH to Omnipod 5 in existing European markets, contributed to this.

Meanwhile, Drug Delivery (for Amgen Neulasta Onpro) was $3 million, down 77.9% year-on-year. The contract with Amgen is scheduled to expire in December 2028, and this business is expected to gradually shrink. However, its share of the total is small at 0.4%, and the impact on the core Omnipod business is limited.

Point 3: Temporary headwinds from medical device corrective actions and peer comparison of diabetes devices

Gross margin was 69.5%, a 240bp decline from 71.9% in the previous year. The primary cause was a voluntary medical device correction for specific lots of Omnipod 5 Pods implemented in March 2026, with related costs estimated at approximately $30 million (approx. 4.7 billion yen), the majority of which is expected to be recorded in 2026. Additionally, inventory obsolescence provisions have increased due to the transition to Omnipod 5.

In peer comparisons, PODD is effectively in a league of its own with its tubeless model. Tandem Diabetes (TNDM) uses tubed pumps and has a revenue scale of just over one-third of PODD's, while the Medtronic Diabetes division is a comprehensive player with both insulin pumps and CGMs. DexCom (DXCM) and Abbott Diabetes Care (ABT division) are pure-play CGM companies but are partners with PODD, maintaining a collaborative rather than competitive relationship. Note that GLP-1 drugs from Eli Lilly and Novo Nordisk are not considered direct competitors because the structure of their treatment is different, and they will be addressed in the risks section below.

Industry-specific KPIs to monitor continuously include: Omnipod revenue growth rate (US +28.3% / International +45.2%, excluding FX), the pace of US type 2 patient acquisition (type 2 indication expansion is underway with Omnipod 5), and CGM integration rates (Dexcom G6/G7, Abbott Libre 2 Plus, and soon Libre 3 Plus).

Biggest Risks: Structural Threat of GLP-1 Drugs and Concentration on a Single Platform

PODD's core risks can be narrowed down to three.

First is the risk of lost opportunities in the type 2 diabetes market due to the widespread adoption of GLP-1 drugs (such as Eli Lilly's Zepbound and Novo Nordisk's Wegovy). For patients whose weight and blood glucose control improve with GLP-1 drugs, the motivation to adopt an insulin pump may weaken. However, for type 1 diabetes patients, insulin administration is essential, and this segment is not directly affected by GLP-1s.

Second is pricing pressure from competitors. Tandem Diabetes and Medtronic Diabetes are each launching next-generation AID products, and if price competition intensifies, a structural decline in gross margin could occur.

Third is the risk of manufacturing capacity bottlenecks. The new Costa Rica plant is under construction, but if demand outpaces supply due to rapid growth, backorders will occur. Dependence on a single source for semiconductor chips (NXP, $96.9 million purchase agreement) also remains an ongoing issue.

Quantitative Thresholds for Monitoring Indicators: Gross margin (current value 69.5% / threshold 68.0% / deviation +1.5pt / if below threshold, a sign of structural deterioration other than corrective measures), International revenue growth rate (excluding FX) (current value +45.2% / threshold +25% / deviation +20.2pt / if below threshold, a sign of slowing international expansion).

Author's View

The verdict is Buy (the current price of $151.28 is below the lower bound of the base scenario range). I will quantitatively constrain the valuation.

As of May 6, 2026, after the Q1 earnings announcement, PODD's stock price is approximately $151, with a market capitalization of approximately $10.6 billion and FY2025 GAAP EPS of approximately $3.46. I anticipate FY2026 consensus EPS of approximately $4.30 (growth rate +24%).

Range Calculation Based on P/E Ratio: A P/E ratio of 40-60x is typical for high-growth medical device stocks. FY2026 EPS $4.30 × P/E 35x = $150 (bearish), × P/E 50x = $215 (base), × P/E 60x = $258 (bullish).

Range Calculation Based on EV/Sales: Assuming FY2026 revenue of approximately $3.3 billion (+22% YoY), EV/Sales 4x = EV $13.2 billion, minus net interest-bearing debt of $470 million = market cap $12.7 billion ÷ 70 million shares = approximately $181 (bearish). EV/Sales 6x = EV $19.8 billion, market cap $19.3 billion ÷ 70 million shares = approximately $276 (base). At EV/Sales 8x, it is approximately $370 (bullish).

Integrating both criteria, the ranges are Bearish $150-$180 / Base $215-$275 / Bullish $300-$370. The current price of $151 is positioned right at the lower limit of the bearish range; if it returns to the base range, there is an upside of +40-80%, and in a bullish scenario, there is potential for doubling.

Quantitative Criteria for Investment Decision (Profitable companies): Revenue growth +15% or more (achieved: +33.9%), profit margin improvement (achieved: SG&A ratio 45.8% → 41.6%), PEG (P/E based on current price is approx. 35x ÷ growth rate 24% = 1.46x, which is below the 2.0x benchmark). Since all three conditions are met and the current price is near the lower limit of the bearish range, I make a clear Buy decision. If one anticipates the full materialization of GLP-1 risks (discussed later), positions should be kept small, but at the current price level, I believe downside risks are largely priced in.

Dividends are zero (no dividend). Capital returns are concentrated on share buybacks, and an ASR of $300 million (approx. 46.8 billion yen) was executed in FY2026 Q1.

Future Business Outlook

Confidence: High — Continued penetration of Omnipod 5 in US type 1 diabetes

Sales in the US pharmacy channel are already established, and the transition to Omnipod 5 and the expansion of the customer base are extensions of past performance. Management indicated in their guidance that the +28.3% US growth is expected to continue this fiscal year.

Confidence: Medium — Full-scale development of the Type 2 diabetes market

While Type 2 indication has been obtained in the U.S. for those 18 and older, the expansion of insurance reimbursement and physician education remain bottlenecks. The company plans to file a 510(k) for a fully closed-loop AID (for Type 2) in 2027 based on the EVOLVE clinical trial, with commercialization expected in 2028 or later. The key will be how they can capture the market for combination therapy with GLP-1 drugs.

Confidence: Low — Revitalization of the non-insulin drug delivery business

The Amgen contract expires in December 2028. Partnerships with new pharmaceutical partners are limited, and currently, this accounts for only 0.4% of revenue. Business restructuring will take time.

Summary

PODD's FY2026 Q1 was a strong quarter with **revenue +33.9% and net income +157%**. The 240bp decline in gross margin due to medical device corrective actions is temporary, the quality of operating profit has improved through SG&A leverage, and medium- to long-term catalysts such as U.S. Type 2 expansion and Omnipod 6 development are ahead. While the structural threat of GLP-1s should be kept in mind, its position as an essential device for Type 1 patients remains unshaken. Overall judgment is Buy (current price of $151 is near the lower end of the bearish range, with a +40-80% upside upon return to the base range of $215-$275). With a PEG of 1.46x, it meets the three investment criteria, and I view the stock price adjustment after the Q1 earnings as an excellent buying opportunity.

Related Article Links

・Insulet PODD Previous Individual Analysis Article:

📊 At U.S. Stock Signal Lab, we delve into growth themes such as AI semiconductors, space, defense, and energy using 10-K/10-Q financial data. By clicking 'Like' and following, you won't miss any new articles. Please feel free to leave a comment if there are any companies you would like us to analyze or if you have any feedback!

#Investment #StockInvestment #USStocks #EarningsAnalysis #PODD #Insulet #DiabetesDevice #Healthcare #10Q